Dyne Therapeutics Inc [DYN] stock is trading at $12.24, up 4.08%. An important factor to consider is whether the stock is rising or falling in short-term value. The DYN shares have gain 4.08% over the last week, with a monthly amount glided 4.44%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Dyne Therapeutics Inc [NASDAQ: DYN] stock has seen the most recent analyst activity on May 29, 2025, when Evercore ISI initiated its Outperform rating and assigned the stock a price target of $46. Previously, BMO Capital Markets started tracking the stock with Outperform rating on March 12, 2025, and set its price target to $50. On March 07, 2025, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $50 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $46 on December 13, 2024. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $45 as its price target on November 26, 2024. JP Morgan downgraded its rating to Neutral for this stock on October 24, 2024, and downed its price target to $35. In a note dated May 21, 2024, Chardan Capital Markets reiterated an Buy rating on this stock and boosted its target price from $31 to $42.
Dyne Therapeutics Inc [DYN] stock has fluctuated between $6.36 and $47.45 over the past year. Currently, Wall Street analysts expect the stock to reach $47 within the next 12 months. Dyne Therapeutics Inc [NASDAQ: DYN] shares were valued at $12.24 at the most recent close of the market. An investor can expect a potential return of 283.99% based on the average DYN price forecast.
Analyzing the DYN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.51, Equity is -0.53 and Total Capital is -0.58. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.83 points at the first support level, and at 11.41 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.50, and for the 2nd resistance point, it is at 12.75.
Ratios To Look Out For
For context, Dyne Therapeutics Inc’s Current Ratio is 20.35. On the other hand, the Quick Ratio is 20.35, and the Cash Ratio is 13.94.
Transactions by insiders
Recent insider trading involved Scalzo Richard William, Officer, that happened on May 16 ’25 when 2479.0 shares were purchased. Officer, Beskrovnaya Oxana completed a deal on May 16 ’25 to buy 2589.0 shares. Meanwhile, Chief Commercial Officer Friedl-Naderer Johanna sold 143.0 shares on Mar 13 ’25.
